logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Regeneron and Moderna Are Both Outperforming Today

Regeneron, Moderna, and COVID-19 The spread of COVID-19 , minute creatures that seem to be trying to defeat us, has been accused of bringing the market down over 1000 points yesterday. Investors who love the biotech stocks they carefully and...

Read More

February 25, 2020

0

Cytokinetics' heart failure drug omecamtiv mecarbil advancing into late phase trials

Cytokinetics’ (CYTK)   investigational product omecamtiv mecarbil , the firm’s potential treatment for heart failure with reduced ejection fraction, is advancing in a late phase clinical trial. Cytokinetics   is conducting METEORIC-HF clinical trial, in collaboration with   Amgen (AMGN),...

Read More

February 23, 2019

0

More About Moderna, Gilead and Forty Seven

Moderna Therapeutics Among all the firms announcing their interest in working towards designing and producing a preventive vaccine for COVID-19 only Moderna ( MRNA ) has accomplished that job and delivered it to the health authorities to decide upon the...

Read More

February 28, 2020

0

Why CRISPR Therapeutics' stock gained around $8 today

CRISPR Therapeutics' (CRSP) s tock added around $8 today while reporting financial results for the fourth quarter and full year ended December 31, 2018. Here is what Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, has stated, “This past year...

Read More

February 25, 2019

0

The Small Firm Whose Stock Soared in Yesterday's Market

Firms' with COVID-19 Vaccines Stock Performance A look at the stock performance of the COVID-19 vaccine firms that have demonstrated early, promising and even good news regarding their prophylactic effect. The outcome was as follows:    Moderna ( MRNA )...

Read More

July 21, 2020

0

Exelixis moves more products into clinical trials. Alnylam's product Givosiran demonstrates efficacy in Acute Hepatic Porphyria (AHP). Why investors have caused a stock selloff.

Thanks to abundant cabozantinib sales’ revenues Exelixis (EXEL) is advancing a new generation of its medicines with its new product XL092 entering clinical trials . The drug is a next-generation oral tyrosine kinase inhibitor that targets VEGF receptors & MET...

Read More

March 6, 2019

0

How the Stock Prices of Firms Developing Treatments or Vaccines Have Started the Day

NanoViricides and COVID-19 NanoViricides ( NNVC ), a development-stage nano-biopharmaceutical company with a proprietary and patented drug development focused on viral diseases, is among the few firms that are actively working on developing products that can treat the coronavirus disease...

Read More

March 6, 2020

0

Gene therapy: Speeding down the road towards offering cures. A small firm might have some good news

We love to read news about gene therapy as it is the only possibility for curing diseases that no known treatment can halt or delay their progression. The attempts to use gene therapy failed ambitious researchers for several decades before...

Read More

March 12, 2019

0

The Small Stock That Refused to Kneel in Today's Market

Compugen Soaring in an Extremely Down Market The stocks' prices tumbled today except for very few and one of them is Compugen ( CGEN ) . This firm announced good news; we wish it has chosen a better day for...

Read More

March 9, 2020

0

The FDA Approved Gilead Sciences CAR T Cell Product Tecartus for Adults with Relapsed or Refractory Mantle Cell Lymphoma

Gilead Sciences CAR T Cell Product Tecartus Gets FDA Approval The U.S. FDA approved Kite - Gilead Sciences ( GILD ) chimeric antigen receptor (CAR) T cell therapyTecartus™ (brexucabtagene autoleucel). Tecartus has become the first and the only approved CAR...

Read More

July 27, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 92
  • 93
  • 94
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy